在近期召开的美国泌尿外科学会年会(AUA)上,美国纽约Rochester大学泌尿外科的Edward Messing博士报道说,对轻微血尿症患者进行家庭膀胱癌筛查可显著改善膀胱癌患者的存活率;该项研究结果证实早期干涉膀胱癌具有重要的临床意义。 Messing博士及其同事对1575例50岁以上的无症状男性志愿者进行膀胱癌筛查,并在研究开始前和8个月后,采用Ames Hemastix试剂条对与检测血尿症显微镜下尿检相关的血红蛋白含量分别进行14天的自我检测。该研究项目始于上世纪80年代后期和90年代初期,受试人群与1988年Wisconsin癌症报告系统收集的509例膀胱癌患者进行对比分析;研究发现筛查结果中有248例可通过显微镜下血尿分析得以确认,其中被确诊的膀胱癌患者为21例。 Messing博士在AUA新闻发布会上解释说,该项研究旨在了解早期膀胱癌筛查的可行性,从而采取适时治疗以改善疾病的进程及预后。经过为期14 At the recent AUA meeting, Dr Edward Messing of the Department of Urology at Rochester University in New York, USA, reported that screening for bladder cancer in families with mild hematuria can significantly improve survival in patients with bladder cancer; The results of the study confirmed that early intervention of bladder cancer has important clinical significance. Messing and colleagues evaluated bladder cancer screening in 1575 asymptomatic male volunteers over the age of 50 years. Ames Hemastix strips were used to assess hemoglobin associated with a urine test taken by a hematuria microscope before and 8 months after the study. Content of 14 days of self-testing. The research project began in the late 1980s and early 1990s with a comparison of 509 patients with bladder cancer collected from the Wisconsin Cancer Reporting System in 1988; 248 of the screening results were detectable by microscopic hematuria The analysis was confirmed, of which 21 cases were diagnosed with bladder cancer. At the AUA press conference, Dr. Messing explained that the study aims to understand the feasibility of early screening of bladder cancer to take timely treatment to improve disease progression and prognosis. After a period of 14